Department of Dermatology and Venereology, Medical Faculty, Medical University, Sofia, Bulgaria.
2nd Department of Dermatology, Cutaneous Lymphoma Unit, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
Clin Dermatol. 2021 Jan-Feb;39(1):64-75. doi: 10.1016/j.clindermatol.2020.12.014. Epub 2021 Jan 9.
Primary cutaneous lymphomas are defined as a heterogenic group of T- and B-cell non-Hodgkin lymphomas that present initially in the skin. Patients with primary cutaneous lymphomas are at a higher risk for developing complications in case of infection with the novel coronavirus severe acute respiratory syndrome coronavirus 2. The coronavirus disease 2019 (COVID-19) pandemic has affected the established diagnostic approach, staging, and therapeutic guidelines in patients with primary cutaneous lymphomas. In the light of the current global health crisis, management of primary cutaneous lymphomas needs to be adjusted. The key to achieving this is to balance the optimal control of the lymphoma, with a minimal increase of the personal risk for COVID-19 exposure and complications.
原发性皮肤淋巴瘤是一组异质性的 T 细胞和 B 细胞非霍奇金淋巴瘤,最初表现为皮肤受累。原发性皮肤淋巴瘤患者在感染新型冠状病毒严重急性呼吸综合征冠状病毒 2 时发生并发症的风险更高。冠状病毒病 2019(COVID-19)大流行影响了原发性皮肤淋巴瘤患者既定的诊断方法、分期和治疗指南。鉴于当前的全球卫生危机,需要调整原发性皮肤淋巴瘤的治疗。实现这一目标的关键是在最大限度地降低 COVID-19 暴露和并发症的个人风险的同时,实现对淋巴瘤的最佳控制。